Redwood Pharma AB (publ) announced that a poster summarizing the company's clinical study with the innovative and revolutionary treatment of dry eye - RP501 - attracted great interest at the annual conference Association for Research in Vision and Ophthalmology, ARVO, in Seattle, USA. The poster was presented by Assoc. Prof. Dr. Gerhard Garhöfer, who was the principal investigator in the study.

RP501 is being developed to be an effective and user-friendly over-the-counter thermogel for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. The results of a clinical study show that RP501 is safe, provides a significant therapeutic effect already at a dosage of 1-2 drops per day and is convenient to use ? characteristics that consumers consider the most important parameters for a dry eye product.

The study was completed in the spring of 2023.